Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Dri Healthcare Trust T.DHT.UN

Alternate Symbol(s):  DHTRF

DRI Healthcare Trust is a Canada-based company engaged in global pharmaceutical royalty monetization. The Company is involved in pharmaceutical royalty monetization and provides capital to inventors, academic institutions and biopharma companies. It acquires more than 25 royalties on 20-plus drugs, including Eylea, Orserdu, Omidria, Spinraza, Stelara, Vonjo, Zejula and Zytiga. Its portfolio includes Empaveli/Syfovre, Eylea I, Eylea II, Ilaris, Natpara, Omidria, Oracea, Orserdu I, Orserdu II, Rydapt, Simponi, Spinraza, Stelara, Vonjo I, Vonjo II, Xenpozyme, Xolair, Zejula, Zytiga, sebetralstat, and others. Its therapeutic areas include hematology, ophthalmology, influenza, endocrinology, dermatology, oncology, neurology, immunology, lysosomal storage disorder, hereditary angioedema, and others. The Company is managed by DRI Capital Inc. Its products are marketed by pharmaceutical companies, including Regeneron, Bayer, Santen; AstraZeneca; Takeda; Galderma Laboratories; and others.


TSX:DHT.UN - Post by User

User Avatar Image
(69)
•••
  • SONOFFERGUSX
Comment by SONOFFERGUSon Apr 19, 2025 1:00pm
85 Views
Post# 36544646

RE:T3 Error Update

RE:T3 Error UpdateHey junglejames.

Annoying.

I bought DHT for the first time in 2024 so spent a minute reconciling the T3 I received from TD Direct. 

The T3 income for cash distributions ties in to the cash received. The distributions were about 0.75% less than the USD0.085/unit converted at Bank of Canada spot for the day.  Fair enough for TD's slice.

The non-cash distribution for December, on the other hand, looks like it was converted at that 1.3698 average exchange rate for the year shown in the "statement of trust income allocations and designations."  Odd, but whatever, as it's understating the dividend.

If your T3 shows amounts that weren't received (cash) or receivable (the non-cash distribution), it is wrong.  If I were you, I would make an entry on Line 12100/9 to adjust to actual.  Describe it like "DRI Healthcare T3 Box 25 -- adjustment to actual amounts per broker's statement" or such.

DHT pays nothing but fully-taxed income, so is best held in exempt or deferred accounts anyway.

Good luck!








<< Previous
Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities